Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan

Annals of Surgical Oncology

Volumn 21, Issue 4, 2014, Pages 1147-1152

  Canbay, Emel ^a   Mizumoto, Akiyoshi ^b   Ichinose, Masumi ^b   Ishibashi, Haruaki ^b   Sako, Shouzou ^a   Hirano, Masamitsu ^b   Takao, Nobuyuki ^b   Yonemura, Yutaka ^a,b  

^a Kishiwada Tokushukai Hospital   (Japan)

^b Kusatsu General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; DIARRHEA; FATIGUE; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; INDUCTION CHEMOTHERAPY; JAPAN; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; MIDDLE AGED; NAUSEA; OVERALL SURVIVAL; PERITONEUM CANCER; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OXONIC ACID; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TEGAFUR;

EID: 84896096157     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3443-2     Document Type: Article

References (23)

1. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynaecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-63. (Pubitemid 30051820)
2. Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol. 2008;98:273-6.
3. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163-8. (Pubitemid 27112884)
4. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24:2903-3909.
5. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and hemohyperthermic peritoneal perfusion. Br J Surg. 2005;92:370-5. (Pubitemid 40445602)
6. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004; 139:20-6. (Pubitemid 38049613)
7. Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004; 8:454-463. (Pubitemid 38561210)
8. Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32:661-65. (Pubitemid 44063995)
9. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009;100:311-16.
10. Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:148420.
11. Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16:3227-36.
12. Fujiwara Y, Takiguchi S, Nakajima K, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol. 2011;18:3726-31.
13. Imano M, Yasuda A, Itoh T, et al. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 2012;16:2190-6.
14. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res. 1996;82:235-53.
15. White SK, Stephens AD, Sugarbaker PH. Hyperthermic intraoperative intraperitoneal chemotherapy safety considerations. AORN J. 1996;63:716-24.
16. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49-68.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2009;92:205-16.
18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101-112.
19. Badgwell B, Cornier JN, Krishnan S, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008;15:2684-91.
20. Lorenzen S, Panzram B, Rosenberg R, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol. 2010;17:2733-9.
21. Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitonel hyperthermic chemoperfusion combined with surgery. Cancer. 1997;79:884-91. (Pubitemid 27089870)
22. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004;139:20-6. (Pubitemid 38049613)
23. Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer withperitoneal metastasis. Ann Oncol. 2010;21:67-70.